Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D and Products
R&D and Products

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

中文简体

English

Home

ABOUT US

NORTHLAND

undefined

View Details

The newly built pharmaceutical plant of Beijing Huonland Pharmaceutical Technology Co., Ltd. has been completed.

undefined

View Details

NORTHLAND is designated as the Beijing International Science and Technology Cooperation Base.

undefined

View Details

NORTHLAND Signs Strategic Cooperation Agreement with Pangen Co., Ltd. (Korea)

undefined

View Details

The three projects under the “Major New Drug Development” special program—the key national science and technology project of the 11th Five-Year Plan—undertaken by the company have successfully passed acceptance testing.

undefined

View Details

Recombinant Human Thymosin β4 Applies for New Drug Clinical Trials

undefined

View Details

NORTHLAND Selected as a Key High-Tech Enterprise under the National Torch Program

undefined

View Details

The main structure of Phase I of the NORTHLAND pharmaceutical production base has been topped out.

undefined

View Details

The first-phase project of the NORTHLAND pharmaceutical production base has officially broken ground.

undefined

View Details

NORTHLAND Holds Groundbreaking Ceremony for Pharmaceutical Production Base Construction Project

undefined

View Details

NORTHLAND has been recognized by the Municipal Science and Technology Commission as an Engineering Technology Research Center.

undefined

View Details

“Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” project has officially launched Phase II clinical trials.

undefined

View Details

The NL002 project has received approval for Phase III clinical trials.

View Details

The signing ceremony for the joint venture established by NORTHLAND, Humedix, and Beijing Lint was held in Beijing.

undefined

View Details

NORTHLAND Wins the Third Prize of the Beijing Science and Technology Award

undefined

View Details

NORTHLAND received financial support for technological innovation from Beijing's science and technology-based SMEs in 2011.

undefined

View Details

NORTHLAND Honored as an Advanced Enterprise in the "Double Love and Double Evaluation" Initiative of Haidian Park, Zhongguancun Science Park

undefined

View Details

NORTHLAND was successfully selected as a Key Enterprise in Haidian District for the 2010-2011 period.

undefined

View Details

The NL005 project has been granted invention patents in the United States and South Korea.

undefined

View Details

NORTHLAND Selected for the Third Batch of Tsinghua Science Park's "Diamond Program"

undefined

View Details

NORTHLAND has been selected as a key enterprise for the first batch of cultivation under the "Gazelle Program" of the Zhongguancun National Independent Innovation Demonstration Zone.

< 1...13 14 15 16 >

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license